• Education
  • Get the app
  • Country
    singapore
    hong kong
    malaysia
    indonesia
    thailand
    philippines
    vietnam
    india

    australia
    korea
    new zealand
The CIMS logo.
  • Home
  • Find Drugs
  • Find Drug Company
  • Diseases
  • Medical News & Updates
The CIMS logo.
Home Find Drugs Find Drug Company Diseases Medical News & Updates
Other Services
CIMS Education Download App
Country
  • a globesingapore
  • a globehong kong
  • a globemalaysia
  • a globeindonesia
  • a globethailand
  • a globephilippines
  • a globevietnam
  • a globeaustralia
  • a globekorea
  • a globenew zealand
The CIMS logo.
Molecular structure pattern
  1. Home icon
  2. Diseases
  3. Asthma
    • Diseases
    • Asthma
  4. Follow Up

Asthma Follow Up

Last updated: 21 September 2026
Reviewed by
Honorary Editorial Advisory Board - JMH test 1PAGINATION TESTMIMS Respirology Honorary Editorial Advisory Board
Follow Up
Monitoring
OverviewHistory and Physical ExaminationDiagnosisManagementFrequently Asked Questions
IntroductionEpidemiologyPathophysiologyRisk FactorsClassification
Clinical PresentationHistoryPhysical ExaminationDiagnosis or Diagnostic Criteria
Laboratory Tests and Ancillaries
Differential Diagnosis
Principles of TherapyPharmacological therapyNonpharmacologicalAsthma ExacerbationsPrevention
Monitoring
Anticholinergics (Inhaled)Antihistamines & AntiallergicsBeta2 Adrenoceptor Agonists (Bronchodilators) (Inhaled)*Beta2 Adrenoceptor Agonists (Bronchodilators) (Oral)*Beta2 Adrenoceptor Agonists (Bronchodilators) (Topical)Bronchodilators (Parenteral)Corticosteroids (Inhaled)Corticosteroids (Systemic)Cough & Cold PreparationsAntiasthmatic Preparations - Combination ProductsLeukotriene ModifiersMonoclonal AntibodiesOther Drugs Acting on the Respiratory SystemXanthinesDisclaimer
OverviewHistory and Physical ExaminationDiagnosisManagementFrequently Asked Questions
IntroductionEpidemiologyPathophysiologyRisk FactorsClassification
Clinical PresentationHistoryPhysical ExaminationDiagnosis or Diagnostic Criteria
Laboratory Tests and Ancillaries
Differential Diagnosis
Principles of TherapyPharmacological therapyNonpharmacologicalAsthma ExacerbationsPrevention
Monitoring
Anticholinergics (Inhaled)Antihistamines & AntiallergicsBeta2 Adrenoceptor Agonists (Bronchodilators) (Inhaled)*Beta2 Adrenoceptor Agonists (Bronchodilators) (Oral)*Beta2 Adrenoceptor Agonists (Bronchodilators) (Topical)Bronchodilators (Parenteral)Corticosteroids (Inhaled)Corticosteroids (Systemic)Cough & Cold PreparationsAntiasthmatic Preparations - Combination ProductsLeukotriene ModifiersMonoclonal AntibodiesOther Drugs Acting on the Respiratory SystemXanthinesDisclaimer

Monitoring

Patients who have started or are starting medication adjustment and have higher risk of poor outcome should be monitored 1-3 months after the first consultation, and then every 3-12 months thereafter. Patients previously seen at primary care due to an exacerbation who were discharged after effectively responding to initial treatment should return for follow-up within 2-7 days after discharge and then 2-3 months thereafter. After an exacerbation, the patient should be seen within 1 week to 1 month until with good symptom control and has reached or surpassed personal best lung function. All asthma patients should follow-up at least twice a year. Lung function should be recorded at the time of diagnosis, 3-6 months after starting treatment, and periodically during follow-up.

Remission of Asthma
 

Remission of asthma often refers to either clinical remission, such as the absence of asthma symptoms or exacerbations for a certain period of time, or complete/pathological remission, which involves normal lung function, airway responsiveness, and inflammatory markers—both of which reflect the goals of long-term management.  

Please see Goals of Therapy in the Principles of Therapy.  

Clinical or complete remission has been observed in adults either spontaneously or after the cessation of controller treatment. It may also be seen in patients with occupational asthma once exposure is discontinued. GINA identifies the need for further research on asthma remission in adults on treatment in order to determine the association between clinical criteria and laboratory results, as well as to identify predictors of remission or recurrence.

The CIMS logo.
  • Drugs
  • Find Drugs
  • Find Drug Company
  • CIMS Abbreviation Index
  • Diseases
  • Search Disease Information
  • Editorial Advisory Board
  • Medical News & Updates
  • Latest News & Updates
  • More Services
  • Education
  • Subscribe
  • About
  • MIMS Corporate
  • Terms of Use
  • Privacy Policy
  • Feedback
Connect with CIMS
A social media brand icon.A social media brand icon.A social media brand icon.A social media brand icon.A social media brand icon.
TUV Nord ISO 9001 certification logo
CIMS Specialty release/v3.16.0_3176.1
Copyright © 2026 CIMS Pte Ltd. All rights reserved. UAT
CIMS Logo

Sign up for Free to continue reading

Already a member?

Sign up for Free to continue reading

Already a member?

Sign up for Free to continue reading

Already a member?
Something went wrong.